FIELD: biotechnology.
SUBSTANCE: described is a genetic construct pMYMK-P2A-ERVW-1, presented in Fig. 1, for separate expression of the MYMK SEQ ID NO: 1 and ERVW-1 SEQ ID NO: 2 genes and enhancing muscle cell fusion.
EFFECT: design of codon-optimised nucleotide sequences of genes coding proteins Myomaker and Syncytin-1 (MYMK and ERVW-1, respectively), as well as multi-cistronic cartridges created on the basis of the genes described above, intended for the expression of Syncitin-1 and Myomaker proteins in an amount sufficient to increase the intensity of the processes of myoblast fusion with muscle fibres.
1 cl, 2 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMISED CDNA CODING HUMAN DYSFERLIN, GENETICALLY ENGINEERED CONSTRUCT, RECOMBINANT ADENOVIRUS AND PHARMACEUTICAL COMPOSITION FOR TREATING DYSFERLINOPATHIES | 2012 |
|
RU2527073C2 |
| NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF | 2004 |
|
RU2397249C2 |
| NON-HUMAN ANIMALS WITH A GYRATE DEFICIENCY | 2014 |
|
RU2721855C2 |
| NOGGIN2-BASED ACTIVIN ACTIVITY BLOCKING METHOD | 2005 |
|
RU2354662C2 |
| METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS AND DISEASES RELATED TO RDH12 | 2017 |
|
RU2764920C2 |
| COMPOSITIONS AND METHODS OF GENETIC MATERIAL DELIVERY | 1994 |
|
RU2174845C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| PRODUCTION OF GLYCOPROTEINS WITH MODIFIED FUCOSYLATION | 2008 |
|
RU2479629C2 |
| METHODS AND COMPOSITIONS FOR MODIFYING TARGET LOCUS | 2015 |
|
RU2704283C2 |
